Chairman Michael J. Farrell - 16 May 2022 Form 4 Insider Report for RESMED INC (RMD)

Role
Chief Executive Officer
Signature
Michael J. Farrell, Chief Executive Officer
Issuer symbol
RMD
Transactions as of
16 May 2022
Net transactions value
-$787,957
Form type
4
Filing time
17 May 2022, 13:20:56 UTC
Previous filing
17 May 2022
Next filing
16 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $327,788 +5,675 +1.4% $57.76 410,935 16 May 2022 Direct F1
transaction RMD ResMed Common Stock Sale $1,115,745 -5,675 -1.4% $196.61 405,260 16 May 2022 Direct F1, F2, F3
holding RMD ResMed Common Stock 3,880 16 May 2022 Lisette and Michael Farrell Foundation
holding RMD ResMed Common Stock 5,090 16 May 2022 Lisette and Michael Farrell Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -5,675 -5.1% $0.000000 105,615 16 May 2022 ResMed Common Stock 5,675 $57.76 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan.
F2 This transaction was executed in multiple trades at prices ranging from $195.10 to $198.04. The price reported above reflects the weighted average sale price.
F3 Includes 30.8872 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan.
F4 Represents date options first became exercisable. Options vest 1/3 per year.